Welcome to our dedicated page for KRTL HOLDING GROUP news (Ticker: KRTL), a resource for investors and traders seeking the latest updates and insights on KRTL HOLDING GROUP stock.
KRTL Holding Group, Inc. (OTC: KRTL) is a multidisciplinary holding company with a focus on pioneering developments in the hemp, cannabis, psilocybin, and alternative wellness sectors. Through its subsidiaries, KRTL Biotech, Inc. and KRTL International Corp., the company aims to revolutionize these industries with cutting-edge technology and strategic partnerships.
Core Business
KRTL Holding Group diversifies its operations across several key sectors, including biotechnology, agricultural technology, and international trade. KRTL Biotech excels in developing proprietary technology and commercial CBD and cannabinoid-based products, while KRTL International focuses on global collaborations and market expansion.
Recent Achievements
KRTL has entered into several strategic agreements to bolster its market presence and innovation capabilities. Notable partnerships include collaborations with Yeungnam University in Korea to advance cannabis education, an agreement with Yuhan Care for cannabinoid product development, and a channel partner agreement with Medflow Inc. for telemedicine technology integration. Additionally, KRTL's successful FDA registration marks a significant milestone in enhancing the U.S. pharmaceutical supply chain.
Current Projects
KRTL is actively involved in the development and distribution of CBD and cannabinoid products. The company's collaboration with Yuhan Care focuses on high-purity CBD extraction and market integration. In Bolivia, KRTL is working with GIH Life Sciences and Industria Quimico Farmaceutica SigmaCorp to advance CBD/THC research and commercialization. KRTL Biotech's innovative telemedicine platform, in partnership with Medflow, leverages AI to enhance patient care in the alternative wellness sector.
Financial Condition
KRTL Holding Group continually seeks to diversify risk and access new markets, ensuring robust financial health. The company's strategic investments and partnerships are designed to generate steady revenue streams and create value for shareholders.
Partnerships and Products
KRTL's extensive network of partnerships includes leading educational institutions, global pharmaceutical companies, and cutting-edge technology firms. These collaborations enable the company to offer a wide range of products, from educational programs to advanced cannabinoid-based health solutions. The company's focus on quality and compliance ensures that all products meet rigorous industry standards.
KRTL Holding Group, Inc. remains committed to innovation, sustainability, and excellence. The company's strategic vision and collaborative approach position it as a leader in the evolving hemp, cannabis, and alternative wellness industries.
KRTL Holding Group (OTC: KRTL) has announced a strategic expansion in Bolivia through a joint venture between its subsidiaries, KRTL Biotech and KRTL International, and Centro de Investigaciones Químicas (CIQ). Each subsidiary secured a 9.99% stake in 3451.5 acres of land in the Amazon region, totaling 689.9 acres.
The partnership aims to establish sustainable API extraction, research, and manufacturing facilities in Bolivia, with three key facilities planned in Quillacollo, Santa Cruz, and Cochabamba. CIQ, led by Dr. Bascope, specializes in extracting high-value botanical ingredients from Bolivia's diverse ecosystems.
Through this venture, KRTL Biotech will introduce CIQ's products, including cosmetics, raw materials, minerals, and APIs, to the U.S. market following FDA registration requirements. The collaboration also provides access to CIQ's exotic molecule library for potential pharmaceutical applications in pain management, anti-inflammatory treatments, and dermatology.
KRTL Holding Group has announced the successful FDA registration of Industria Químico Farmaceutica SIGMA CORP (SIGMA), a Bolivian pharmaceutical company, obtaining their Federal Establishment Identifier (FEI). This milestone enables access to the U.S. market and highlights the partnership between KRTL and SIGMA in advancing regulatory readiness.
The collaboration aims to leverage Bolivia's rich biodiversity and natural resources in the pharmaceutical sector. According to the U.S. Department of Commerce, Bolivia presents untapped potential in pharmaceutical manufacturing and export capabilities. The FDA registration demonstrates both companies' commitment to regulatory excellence and quality manufacturing, positioning Bolivian-manufactured pharmaceuticals for global market opportunities.
KRTL Biotech Inc., a wholly owned subsidiary of KRTL Holding Group Inc. (OTC: KRTL), has acquired a 55% majority stake in Skidmore Companies , now rebranded as Nutrivance Global. The acquisition leverages KRTL's Active Pharmaceutical Ingredients (APIs) portfolio with Nutrivance Global's established government and private distribution networks.
The deal includes a sophisticated data platform for real-world decision-making, enhancing distribution efficiency and partner insights. The partnership aims to expand distribution of KRTL's APIs, FDA-approved food and beverage products, and cosmetic lines internationally. A revenue-sharing structure has been implemented to ensure transparent management and accelerate market reach.
The collaboration combines Nutrivance Global's distribution expertise and regulatory compliance capabilities with KRTL's product portfolio, positioning both companies to address growing global demand for APIs and advanced solutions.
KRTL Holding Group's subsidiary, KRTL Biotech, has successfully registered SIGMACORP with the FDA as a U.S. pharmaceutical manufacturer. Acting as SIGMACORP's U.S. Registered Agent, KRTL Biotech aims to facilitate international pharmaceutical integration and diversify the U.S. healthcare supply chain.
This registration enables SIGMACORP to manufacture pharmaceutical products for the U.S. market, potentially introducing more affordable healthcare solutions. The partnership focuses on expanding market opportunities, enhancing competitive advantages, and supporting U.S. healthcare resilience through supply chain diversification.
The milestone strengthens U.S.-Bolivia relations in the healthcare sector and positions KRTL Biotech as a leader in international pharmaceutical collaboration.
KRTL Biotech, a subsidiary of KRTL Holding Group (OTC: KRTL), has achieved FDA registration, marking a strategic milestone in strengthening the U.S. pharmaceutical supply chain. The registration positions KRTL to facilitate international manufacturers' entry into the U.S. market, focusing on delivering high-quality active pharmaceutical ingredients (APIs) and finished products. The company plans to establish a manufacturing and distribution facility in 2025 to support both domestic and international partners. This initiative aims to provide lower-cost alternatives and optimized logistics solutions, enhancing supply chain stability while generating cost savings for the healthcare sector.
KRTL Holding Group, Inc. (OTC: KRTL) has announced a memorandum of understanding (MOU) with Yuhan Care, a subsidiary of the esteemed Yuhan Corporation. This collaboration focuses on developing CBD and cannabinoid-based products aimed at both the US and Korean markets. The agreement leverages KRTL’s established manufacturing partners and Yuhan’s expertise in cannabinoid research, promising high-quality products. Both companies aim to enhance their global footprint in the cannabis industry, with Yuhan being the first representative of CBD research in Korea's Hemp Free Zone.
KRTL Holding Group has welcomed Mr. David Beling as a Strategic Advisor, bringing over 50 years of mining experience. A graduate in Mining Engineering, Beling has contributed to various mining projects and companies, including Bullfrog Gold Corp and Geovic Mining Corp. His extensive background includes overseeing the development of significant mining operations and raising substantial capital. Beling expressed enthusiasm about enhancing KRTL's business model and production plans, indicating a promise for growth and profitability.
KRTL International Corp. (OTC: KRTL) has formed a strategic alliance with Cannabis Global, Inc. (OTC: CBGL) to enhance infusion technologies in the hemp and cannabis markets. This collaboration aims to develop water-soluble formulations and proprietary delivery methods for a variety of products. The partnership intends to leverage shared R&D and marketing strategies, allowing both companies to potentially access international markets, particularly in Asia. KRTL plans to showcase these innovations at the MJ BIZ CON event in November 2022.